• Developing the first off-the-shelf personalized immunotherapy for advanced breast cancer, Bria-OTS. Bria-OTS is designed to provide personalized treatment for ~90% of the advanced breast cancer patients without the high costs and difficult manufacturing associated with personalized treatments. The technology may be applicable to other cancers.
• Addressing an unmet need by targeting advanced breast cancer, from which an estimated 40,000 women have died in U.S. in 2017
• $1 billion-$5 billion market opportunity depending on patient treatment stage
• Results of two completed proof-of-concept human clinical trials showed rapid tumor shrinkage at multiple sites in advanced breast cancer patients without toxicity associated with other oncology treatments (e.g. chemotherapy).
• Bria-IMT has completed enrollment of a Phase I/IIa clinical trial with outstanding safety data and early signs of potent efficacy. Preliminary data from the Phase I/IIa trial is expected in 3Q2018.
• BriaDX, a companion diagnostic test, is currently in development along with Bria-IMT and Bria-OTS.
• Experienced management has been involved in over 10 drug approvals
• Significant near-term news-flow

BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT with Keytruda (Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy (Yervoy is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX. By using BriaDX to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

For more information, visit the company’s website at www.BriaCell.com

• Directors Yaqing Hu and Hui Zhu have stepped down for personal reasons
• Hongxiang Yu named chairman of the audit committee
• Yilei Shao appointed chair of the compensation committee

TMSR Holding Company Limited (NASDAQ: TMSR), a company that through its subsidiaries develops, produces and sells patented industrial and mining waste management solutions, has announced changes in the membership of its board of directors. Two directors, Yaqing Hu and Hui Zhu, have resigned from their roles on the board due to personal reasons. Their resignations took effect at the end of August, according to a company news release (http://ibn.fm/5Mr1U).

Stepping in to take their places will be Hongxiang Yu and Yilei Shao. The board appointed Yu as chairman of the audit committee, while Shao will serve as the chair of the compensation committee.

Yu has a strong track record of business leadership. He has served on the board of directors of American Lorain Corporation (NYSE: ALN), a food manufacturing company, and has held senior management positions with Hongrun Construction Group Co. Ltd., asset management and private equity investment firm Shanghai Highlights Asset Management Co. Ltd., and film investment company Tianjin Dragon Film Limited. Yu was educated at the University of Portsmouth in the United Kingdom, where he received a bachelor’s in international trade and a master’s in international human resources management.

Shao has been nominated to serve on the board of American Lorain Corporation. She is the founder and chief executive officer of Shanghai Jianshi Management Consulting Limited and worked for five years in New York as vice president of Goldman Sachs’ Credit Derivatives Department. Her educational background is in computer science, with a bachelor’s degree from Shanghai Jiao Tong University and a doctorate from Princeton University.

Paying tribute to the departing board members, TMSR Chairwoman Jiazhen Li said, “We’d like to thank Zhu and Hu for their leadership, guidance and dedication to TMSR while serving as members of the Board. We are also very delighted that Yu and Shao have agreed to join our Board and look forward to their expertise and insights in helping further strengthen our Board.”

TMSR, through its subsidiaries Shengrong Environmental and Wuhan HOST Coating Materials, is involved in the development, production and sale of industrial waste management systems and solutions. The company holds two international U.S. patents and six patents issued by the People’s Republic of China, including three invention patents and three utility model patents. Using these technologies, Shengrong Environmental recycles solid waste from a number of industries in the People’s Republic of China, extracting usable materials in processes that do not release dangerous chemical discharge.

TMSR’s technology allows the extraction and recycling of usable material from aluminum slag, red mud manganese tailings, copper mine tailings and iron mine tailings. In addition to its involvement in industrial and mining waste processing and recycling, TMSR also trades in iron ore and operates wine import and resale services.

For more information, visit the company’s website at www.TMSRHolding.com

• EMHTF named as a cannabis supplier for Newfoundland Labrador Liquor Corporation (NLC) to serve the adult use market of the entire province of Newfoundland and Labrador
• Pure Sunfarms, in which EMHTF is a 50-50 joint venture partner, has received from Health Canada an amendment permitting it to expand its cannabis production area to 550,000 sq. ft.
• EMHTF already has supply agreements with the Canadian provinces of British Columbia and Ontario; as a cannabis producer, it is ramping up operating facilities in British Columbia and Quebec

Emerald Health Therapeutics Inc. (TSX.V: EMH) (OTCQX: EMHTF) is well positioned in Canada in the adult use cannabis market, both as a supplier to several provinces and as a grower. Through its licensed subsidiary, Emerald Health Botanicals Inc. (“EHB”), it can sell in Canada both medical dried cannabis and cannabis oils (http://ibn.fm/knaK5).

EMHTF, based in Victoria, British Columbia, is focused on developing cannabis as a supplier and cultivator, developing value-added products for the pharmaceutical, nutraceutical and botanical markets with wellness and medical benefits.

Through its EHB subsidiary, it maintains a joint venture with Village Farms International Inc. Together, they operate Pure Sunfarms, which has an existing 1.1 million sq. ft. licensed greenhouse in Delta, British Columbia (Delta 3). An amendment to its cultivation license expands its cannabis production area to half of that facility. Full production is expected by mid-October (http://ibn.fm/KFdG4).

EMHTF also owns Agro-Biotech, a Quebec-based licensed cannabis grower operating a 75,000 sq. ft. licensed indoor facility. It is planning to add a 500,000 sq. ft. greenhouse in Metro Vancouver, Canada.

As a supplier, the company has expanded into a new market by being named by the Newfoundland Labrador Liquor Corporation as supplier to the province of Newfoundland Labrador in Canada for adult use cannabis starting in October. That is in addition to its prior agreements to supply both Ontario and British Columbia (http://ibn.fm/pG5tC).

“We’re proud to work with the NLC as a preferred Licensed Producer to serve Newfoundland and Labrador in the upcoming legal cannabis market,” Chris Wagner, CEO of Emerald, stated in a news release. “This represents the third provincial agreement for our team and we expect to share additional supply updates in the future.”

For more information, visit the company’s website at www.Emerald.care

• Cannabinoid molecule extraction, quantification mark early successes in PreveCeutical’s drug delivery development process
• PreveCeutical optimistic about prototypical spray applicators in development for cannabinoid therapies
• Clinical trials of cannabis-based therapeutics anticipated next year

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is celebrating the achievement of several key milestones in the development of the company’s proprietary Sol-gel program for the nasal delivery of select medications, where those medications can be expected to effectively reach the nervous system in order to accomplish their purposes in treating conditions ranging from anxiety to head concussion injuries, a company officer told market reporting outlet Proactive Investors Limited.

PreveCeutical Chief Research Officer Harry Parekh told Proactive Investors in a September 10 interview (http://ibn.fm/TphxA) that one significant advancement that the company has made is in the extraction of key cannabinoid molecules from one strain received from PreveCeutical’s licensed producer, Canadian cultivator and distributor Aurora Cannabis, Inc. (TSX: ACB) (OTCQX: ACBFF). PreveCeutical’s R&D department was able to validate the chemistry of the cannabinoids within a cannabinoid-rich mixture, measuring them against eight commercial cannabinoid standards over a broad concentration range.

The researchers were then able to quantify how many cannabinoids were present within the extract, ensuring that the amount fell well within the range of what Aurora had specified and clearing the way for the researchers to move forward in assaying four additional strains (http://ibn.fm/3p5NC).

“We’re very confident now moving forward, developing a standard operating procedure to extract it,” Parekh noted in the interview. “At PreveCeutical, we’re working with five different strains which have different concentrations of cannabinoids to THC, and the whole plan here is to develop a range of products which can then be personalized to the patient and also to the disease as the clinical trials data becomes available.”

Through the extraction work, PreveCeutical’s researchers will be able to create a library of chemically fingerprinted cannabinoid extracts that can then be optimized and incorporated into the company’s Sol-gel technology.

PreveCeutical’s ultimate aim is to use its Sol-gel formulations to deliver the cannabis-based therapeutics in a healthful, rapidly catalyzing non-smoked method to assist patients dealing with pain, inflammation, anxiety, seizures and other neurological disorders. The nasal application of the Sol-gels provides the means for the medication to cross the blood-brain barrier without having to run the gauntlet in the gut first, delivering medications with the fewest side effects possible.

Parekh said that the company expects to begin clinical trials by late next year. The research work is being conducted through PreveCeutical’s partner, the University of Queensland’s Pharmacy Australia Centre of Excellence. The university has received several prototypes from its contracted drug delivery device manufacturer for the in-development spray applicator that will ultimately be used to administer the Sol-gels, and it has been assessing their performance.

“We’ve now honed in on a couple of devices which are very promising with our Sol-gel platform,” Parekh said. “It’s interesting because I’ve attended a number of different seminars over the last six to 12 months, looking at other companies that are working in the spray area, and inadvertently when you listen to these seminars you understand some of the complexities that can arise because of the number of sprays that those patients will need to administer. You’re talking upwards of one or two dozen sprays every 24 hours, which is effectively the patient drinking it post-nasally. And so we believe at PreveCeutical we’re going to have the edge on this because our spray will gel as soon as it hits the nasal mucosa, avoiding any post-nasal swallowing, and therefore applications from maybe once or thrice a week will be what we’ll be targeting.”

PreveCeutical is expecting to take advantage of the heightened public interest in cannabis-related medications worldwide. Parekh said that the company has also ensured that the anticipated formulation will be safe for use by all ages from neonate to elderly, with no age-based detrimental effects, and the researchers are looking at multiple ways of channeling the dosage, such as wafers and tablets, in addition to the sprays.

At the same time, the drive to legalize cannabis may create challenges for the company, as much of the available supply is channeled toward recreational use instead of medicinal use, he said. However, PreveCeutical still anticipates a bright future of using its positioning to tailor its products’ well-defined chemistries and delivery methods to patients’ needs.

For more information, visit the company’s website at www.PreveCeutical.com

• Legal cannabis market likely to be plagued by poor quality control
• DNAX technology tracks all stages of cannabis supply chain
• Platform already deployed by biosciences company

Liberalization may be bringing cannabis consumption out of the shadows, but large parts of the supply chain remain hidden – an inconspicuous circumstance that poses great risk to consumers. In New Haven, Connecticut, about 100 people overdosed on “synthetic marijuana” recently, and they may have had no idea that their pot was “synthetic.” Synthetic marijuana can be made to look like the real thing. Technology from BLOCKStrain Technology Corp. (TSX.V: DNAX) (OTC: BKKSF) may have saved these unfortunate individuals from such dire straits. The company’s blockchain system can accurately track all stages of the cannabis supply chain and all aspects of quality control. It could make licensed cannabis retailers and dispensaries as safe as houses.

It’s not good practice to shop for weed in a park, the course of action taken by the 100 or so people who succumbed to the noxious effects of the manufactured variant. Synthetic marijuana, also called K2 or Spice, is composed of a mix selected from a grab bag of chemicals designed to stimulate cannabinoid receptor sites in the brain (http://ibn.fm/aojzw). These synthetic cannabinoid chemicals were first created as research tools to study the brain but are now finding their way into recreational use. Many formulations originate in Asian laboratories. They are purchased by cartels or street dealers, who use them to spray inert plant material before passing off the final product as marijuana.

Cannabis bought through a licensed retailer should be safer, but it may not always be. Although cannabis marketed to the public is subject to testing, state regulatory requirements vary and, more disturbingly, so too does the quality of services provided by the testing industry. The labs that provide these services assess THC levels and test for the presence of plant disease and contaminants. They are an essential aspect of effective regulatory oversight and are expected to abide by state-instituted standards in their testing procedures. However, since the facilities are neither graded nor regularly inspected, it’s difficult to say to what extent compliance is observed. As a result, the industry is plagued by lax practices that may allow substandard or fake cannabis to get to consumers. The need for a system like the one developed by DNAX is becoming more pressing as use of marijuana grows.

Regulators are acutely aware of the risks posed by present supply channels, and so a primary goal is to “establish an efficient, accountable and transparent system for regulatory oversight of the supply chain”, as noted in “The Final Report of the Task Force on Cannabis Legalization and Regulation” published by the Canadian government (http://ibn.fm/Knm38). To accomplish this, requires a system that collects and manages a tremendous amount of data, including pesticide use and quality control, as well as possession limits and servings sizes in order to validate and verify products.

DNAX’s BLOCKStrain platform can do all that and more. The technology can provide the integrity that the current system so sorely lacks. It goes further by ensuring product authenticity and IP protection with a genetics verification process. Using BLOCKStrain is also likely to enhance brand reputation. Producers and marketers can take advantage of this novel methodology by submitting the lab results of tested samples to BLOCKStrain. Each time an item is tested and verified by the network, a registration affidavit is auto-generated and given a unique “BLOCKStrain Address” along with a traceable QR Code. Producers, patients and consumers are able to not only verify the test but also rate the product, write reviews and share opinions. These details are stored within BLOCKStrain and, like the test results, cannot be tampered with or modified. Both verification and certification are earned by all parties for their participation. Moreover, pre-existing data on genetic cannabis strains can be submitted to the BLOCKStrain verification administrators, and those results will be added to the user’s blockchain account.

BLOCKStrain has already deployed the technology. Recently, it announced that it had signed a letter of intent to integrate its proprietary technology into Abattis’s product and services ecosystem (http://ibn.fm/m9DbR). Through this collaboration, the parties hope to enable Abattis’ clients to instantly arrange for sales, shipping, testing and analysis of Abattis products, giving those clients comprehensive visibility over such products throughout their entire lifecycles. Abattis is a life sciences and biotechnology company that aggregates, integrates and invests in cannabis technologies and biotechnology services for the legal cannabis industry in Canada.

For more information, visit the company’s website at www.BLOCKStrain.io

• The company is entering the European hydroponics market as it expands its foothold in the cannabis supply marketplace through its first order program via Amazon UK
• SGMD estimates that its revenue will reach $30 million by 2019 with operating profitability and positive operating cash flow; it is increasing its commitment to the industrial hemp sector
• The European marijuana market is seen as becoming the largest cannabis market in the world, with more than $150 million invested already

Sugarmade, Inc. (OTC: SGMD) is targeting the European hydroponics market, supplying multiple products for cultivators via its first order through the Amazon UK program. Its agreement calls for it to offer several dozen stock keeping units (SKUs) to be sold in the United Kingdom. A cannabis-related supply company, SGMD projects that its 2019 volume will reach $30 million at operating profitability (http://ibn.fm/8m7iT).

In a news release, Jimmy Chan, CEO of SGMD, said, “While we have previously informed our investors of our $30 million revenue goal for next year, revenues continue to grow across the board.” He cited the opportunities presented by the lack of available quality products at attractive prices within the European market.

Sugarmade is entering Europe at a time when a new report by analyst group Prohibition Partners projects that, referencing a survey of 28 key countries across the continent, the marijuana market there will be worth €115 billion by 2028. It is seen as becoming the world’s single largest region for cannabis (http://ibn.fm/M0l7U).

SGMD, based in Monrovia, California, recently returned to the OCTQB Venture Market as a fully reporting company (http://ibn.fm/ko4wr). It is a hydroponics supply company committed to growth in the industrial hemp sector. SGMD is a product and brand marketing company with numerous operations, such as packaging and paper goods for diverse industries. By entering the industrial hemp market, it is seeking to increase its revenue base. Its brands include ZenHydro.com, CarryOutSupplies.com and BudLife.

“We not so much believe, but very much know that Europe will become the biggest cannabis industry in the world, it’s just a matter of when,” Stephen Murphy, co-founder and managing director of Prohibition Partners, noted in the report. “The European market has grown faster in the past six months than it has in the past six years.” The article noted that medical cannabis is currently legal in 20 countries across Europe. In 2018, three more announced legalization efforts, and more than $150 million has been invested in those markets already, per the report.

Sugarmade is investing in Hempistry, Inc., a privately held Nevada corporation, which has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain in Kentucky. Additionally, Sugarmade expects to sign an agreement with Hempistry for hemp cultivation supplies.

For more information, visit the company’s website at www.Sugarmade.com

• Partnership with Canopy Growth leverages the network, expertise and innovation capabilities of the world’s largest cannabis company
• Diversified portfolio of high-quality licensed cannabis producers, late-stage applicants, ancillary products and brands
• Investments tailored to meet unique needs of each counterparty while achieving positive cash flow, secured downside protection and upside equity optionality
• Access to an alternative investment vehicle characterized by early entry points, detailed counterparty due diligence and distinguished partners

Canopy Rivers Corporation is the venture capital investment platform of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

• Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
• CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
• Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
• James E. Wagner Cultivation Ltd. (TSX.V: JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
• LiveWell Foods Canada Inc. (TSX.V: LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
• PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
• Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
• Solo Growth (TSX.V: ALZ) is a premiere retail cannabis distributor that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Canada’s largest private liquor retailer, Solo Liquor, who collectively have more than 50 years of regulated substance retail experience. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy as “Solo Growth Corp.”
• Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
• TerrAscend Corp. (CSE: TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
• Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

For more information, visit the company’s website at www.CanopyRivers.com

• Matthew Dole appointed as senior vice president of business development
• Jeff Palumbo appointed as chief technology officer
• New management part of a strategic plan to increase shareholder value and brand awareness

Green Hygienics Holdings Inc. (OTC: GRYN), a cannabis cultivation company targeting the high-end medical and adult-use recreational market, recently announced that it has appointed two new professionals to its management team. Matthew Dole and Jeff Palumbo bring years of leadership experience to Green Hygienics Holdings. The full announcement can be viewed at http://ibn.fm/tUDRM.

Appointed as senior vice president of business development and director, Matthew Dole is a highly skilled business development manager. His extensive background in the health care insurance industry will help him successfully lead Green Hygienics’ business development and expansion initiatives.

Jeff Palumbo, the new chief technology officer (CTO) of Green Hygienics, has successfully created multiple platforms empowering publishers and merchants while engaging consumers. He has developed platforms for several Fortune 1000 companies and is an experienced mentor for start-ups. His expertise will be used to establish global consumer brands for Green Hygienics.

The additions of Dole and Palumbo to its management team are part of a strategic move by the company to grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions and creating trusted global consumer brands. The experience that each brings to the company is invaluable and holds the promise of increasing shareholder value and brand awareness in an increasingly competitive industry.

The philosophy of the company can be found within its name. Hygienics is the science of preserving and promoting the health of individuals, communities and the planet, and it’s at the core of the company’s operations. By producing premium cannabis products at significantly lower costs per gram than its direct competitors, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. Combined with its highly experienced management team, Green Hygienics is on a strategic path to becoming a highly sought after and successful brand.

For more information, visit the company’s website at www.GreenHygienicsHoldings.com

• Proprietary branding and partnership model for consumer-focused cannabis brands
• Expansion includes acquisition of Asher House Pet CBD brand of U.S. hemp-derived cannabidiol supplements for pets
• Footprint growing in billion-dollar Asian nutraceuticals market with Fitamins CBD brand
• Cannabis industry growing at accelerated rate, with North American market expected to top $47 billion by 2027

Cannabis Strategic Ventures, Inc. (OTC: NUGS) is making good on its commitment to stakeholders as it moves forward on a previously announced strategy to develop a proprietary branding and partnership model for consumer-specific cannabis brands and secure several strategic acquisitions.

“Branding is becoming more important to the development of this industry,” Simon Yu, Cannabis Strategic’s CEO, stated in a news release announcing the company’s plans (http://ibn.fm/OGCCq). “As a firm, we predict consumer-focused cannabis brands will eventually become one of the largest categories in the cannabis industry. This is a place we want to be in and are taking steps to ensure our participation. Additionally, as the cannabis industry continues to evolve, the Cannabis Strategic Ventures business model will adapt to the changing needs of the market while remaining true to our core mission.”

Although headquartered in Los Angeles, California, Cannabis Strategic’s outlook is global, with an eye toward supporting entrepreneurial growth within the fast-growing legal cannabis sector. Reemphasizing the company’s belief that cannabis consumer brands are the future of success in the rapidly expanding marketplace, Cannabis Strategic notes that it has taken several steps toward implementing its new brand forward strategy:

• Acquisition of a controlling interest in the Asher House Pet CBD line, a brand of U.S. hemp-derived cannabidiol (CBD) supplements for pets that is gaining national attention and expanding on an international scale (http://ibn.fm/7DUi8).
• Investment into billion-dollar Asian-American nutraceuticals market with acquisition of Fitamins CBD brand, which has access to 600 wholesalers (http://ibn.fm/mIuuP).
• Wholly owned subsidiary Pure Applied Sciences commenced production of its patent-pending Halo Filters, a cannabis smoke filtration pre-rolled cone (http://ibn.fm/LJnRI).
• White label services agreement signed with Sunniva’s CP Logistics subsidiary to produce ultra-purified cannabis extracts for the Pure Organix™ brand owned by Pure Applied Sciences (http://ibn.fm/5KUtt).

Yu said that Cannabis Strategic’s commitment to “continue to evolve to do right for our investors, the industry, our customers, and everyone involved throughout the supply chain” was at the core of the company’s recent decision to conduct a major share restructuring. A total of 75.6 million shares were cancelled, including 20 million from Yu, in a move designed to increase value for all shareholders, a news release states (http://ibn.fm/O9ojV). The decision will also allow company managers, consultants, minority shareholders, and other key Cannabis Strategic Ventures stakeholders to increase corporate flexibility relative to future brand-oriented strategic acquisitions and partnerships.

“The share cancellations increase value for all shareholders and signals to minority shareholders on the management team’s interest in building long-term value for all,” Yu said in the release. “The future of Cannabis Strategic Ventures is all about acquiring and partnering with the best brands in the fast-growing cannabis marketplace. The streamlined share structure will continue to make our Company an attractive partner as we work toward signing other similar brands and distribution partnerships.”

The legal cannabis industry will see a huge growth spurt over the next 10 years, according to Arcview Market Research and partner BDS Analytics. Spending on legal cannabis worldwide is expected to hit $57 billion by 2027, with the majority of those sales – just over $47 billion – coming from North American buyers, an article in Forbes reports (http://ibn.fm/yaKun).

Cannabis Strategic plans to be at the forefront of this revolution as it incubates, develops and partners with category leaders within the cannabis sectors. The company pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations and branded products within the cannabis space, in addition to providing mentorship and a range of essential services to emerging and existing cannabis consumer brands.

For more information, visit the company’s website at www.CannabisStrategic.com

• ChineseInvestors.com is a fintech company
• It provides financial information for Chinese-speaking investors
• The company is in the process of spinning off its cannabidiol (CBD) division

ChineseInvestors.com, Inc. (OTCQB: CIIX) is a fintech company that concentrates on providing financial information and services. Its focus is on operating the foremost financial information website for Chinese-speaking investors. The company provides real-time market commentary, analysis and education-related services via www.ChineseFN.com. ChineseInvestors.com has corporate offices in San Gabriel, California; New York, New York; and Shanghai, China.

Furthermore, the company has recognized opportunities in the U.S. cannabis industry. It has worked to take advantage of the increasing demand for cannabidiol-based nutrition and health products. However, its intention is to focus back on its original mission of providing financial information and services to the greater Chinese community in the United States and internationally. As a result, ChineseInvestors.com is progressing on its initiative to spin off its CBD division, ChineseHempOil.com, Inc.

On January 31, 2017, the company formally launched the website for subsidiary ChineseCBDoil.com. This portal is the world’s first CBD health products online store in the Chinese language. The website offers an array of nutritional supplements containing CBD. Products include purified CBD oil; concentrated CBD; CBD extract liquid; CBD balm; CBD food; and CBD drinks. These offerings are targeted at Chinese-speaking customers around the world.

Warren Wang, ChineseInvestors.com’s chief executive officer, is hopeful that the spinoff of the company’s CBD subsidiary, ChineseHempOil.com, Inc., will be completed by the end of 2018. In a news release, Wang stated, “We intend to continue to expand our consumer division by dedicating more resources to marketing hemp-based CBD products both domestically and in China. At the same time, we will continue to offer our core financial subscription services with a focus on increasing subscription revenues through targeted marketing of the company’s new cryptocurrency subscription services and educational products.”

The drive to legalize hemp is gaining traction. Forbes reported recently that the U.S. Senate voted to legalize hemp after a decades-long ban under marijuana prohibition (http://ibn.fm/B1LUZ). Therefore, to meet the growing demand, ChineseHempOil.com is planning to expand its operations to more U.S. States, as well as Canada and Asian markets (http://ibn.fm/fZ0iH).

ChineseInvestors.com’s CBD division is an attractive asset. For fiscal year 2018, the company reported a 41 percent year-over-year increase in revenues. It ascribes most of the growth to consumer product sales via its wholly owned subsidiaries, ChineseHempOil.com Inc. and CBD Biotechnology Co., Ltd.

Nonetheless, the company, upon completion of its CBD assets spin off, will return to its foundation in consulting, brand building and education for the Chinese-speaking community. While strategically centering on CBD hemp sales, it also has plans to create a cryptocurrency ATM network and a domestic online coin-to-coin exchange for Chinese cryptocurrency investors (http://ibn.fm/X94xT). ChineseInvestors.com continually seeks new growth channels to build its business and shareholder value.

For more information, visit the company’s website at www.ChineseInvestors.com